Remaining Life Expectancy With and Without Polypharmacy: A Register-Based Study of Swedes Aged 65 Years and Older

Jonas W. Wastesson, Vladimir Canudas-Romo, Rune Lindahl-Jacobsen, Kristina Johnell

Research output: Contribution to journalArticle

Abstract

Objectives: To investigate the remaining life expectancy with and without polypharmacy for Swedish women and men aged 65 years and older. Design: Age-specific prevalence of polypharmacy from the nationwide Swedish Prescribed Drug Register (SPDR) combined with life tables from Statistics Sweden was used to calculate the survival function and remaining life expectancy with and without polypharmacy according to the Sullivan method. Setting: Nationwide register-based study. Participants: A total of 1,347,564 individuals aged 65 years and older who had been prescribed and dispensed a drug from July 1 to September 30, 2008. Measurements: Polypharmacy was defined as the concurrent use of 5 or more drugs. Results: At age 65 years, approximately 8 years of the 20 remaining years of life (41%) can be expected to be lived with polypharmacy. More than half of the remaining life expectancy will be spent with polypharmacy after the age of 75 years. Women had a longer life expectancy, but also lived more years with polypharmacy than men. Discussion: Older women and men spend a considerable proportion of their lives with polypharmacy. Conclusion: Given the negative health outcomes associated with polypharmacy, efforts should be made to reduce the number of years older adults spend with polypharmacy to minimize the risk of unwanted consequences.

Original languageEnglish (US)
Pages (from-to)31-35
Number of pages5
JournalJournal of the American Medical Directors Association
Volume17
Issue number1
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

Polypharmacy
Life Expectancy
Pharmaceutical Preparations
Life Tables
Sweden
Half-Life

Keywords

  • Aged
  • Drug use
  • Life expectancy
  • Polypharmacy
  • Sex difference

ASJC Scopus subject areas

  • Medicine(all)
  • Nursing(all)
  • Health Policy

Cite this

Remaining Life Expectancy With and Without Polypharmacy : A Register-Based Study of Swedes Aged 65 Years and Older. / Wastesson, Jonas W.; Canudas-Romo, Vladimir; Lindahl-Jacobsen, Rune; Johnell, Kristina.

In: Journal of the American Medical Directors Association, Vol. 17, No. 1, 01.01.2016, p. 31-35.

Research output: Contribution to journalArticle

Wastesson, Jonas W. ; Canudas-Romo, Vladimir ; Lindahl-Jacobsen, Rune ; Johnell, Kristina. / Remaining Life Expectancy With and Without Polypharmacy : A Register-Based Study of Swedes Aged 65 Years and Older. In: Journal of the American Medical Directors Association. 2016 ; Vol. 17, No. 1. pp. 31-35.
@article{5c3487b1363047dd8a2a79956aabd6e8,
title = "Remaining Life Expectancy With and Without Polypharmacy: A Register-Based Study of Swedes Aged 65 Years and Older",
abstract = "Objectives: To investigate the remaining life expectancy with and without polypharmacy for Swedish women and men aged 65 years and older. Design: Age-specific prevalence of polypharmacy from the nationwide Swedish Prescribed Drug Register (SPDR) combined with life tables from Statistics Sweden was used to calculate the survival function and remaining life expectancy with and without polypharmacy according to the Sullivan method. Setting: Nationwide register-based study. Participants: A total of 1,347,564 individuals aged 65 years and older who had been prescribed and dispensed a drug from July 1 to September 30, 2008. Measurements: Polypharmacy was defined as the concurrent use of 5 or more drugs. Results: At age 65 years, approximately 8 years of the 20 remaining years of life (41{\%}) can be expected to be lived with polypharmacy. More than half of the remaining life expectancy will be spent with polypharmacy after the age of 75 years. Women had a longer life expectancy, but also lived more years with polypharmacy than men. Discussion: Older women and men spend a considerable proportion of their lives with polypharmacy. Conclusion: Given the negative health outcomes associated with polypharmacy, efforts should be made to reduce the number of years older adults spend with polypharmacy to minimize the risk of unwanted consequences.",
keywords = "Aged, Drug use, Life expectancy, Polypharmacy, Sex difference",
author = "Wastesson, {Jonas W.} and Vladimir Canudas-Romo and Rune Lindahl-Jacobsen and Kristina Johnell",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.jamda.2015.07.015",
language = "English (US)",
volume = "17",
pages = "31--35",
journal = "Journal of the American Medical Directors Association",
issn = "1525-8610",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Remaining Life Expectancy With and Without Polypharmacy

T2 - A Register-Based Study of Swedes Aged 65 Years and Older

AU - Wastesson, Jonas W.

AU - Canudas-Romo, Vladimir

AU - Lindahl-Jacobsen, Rune

AU - Johnell, Kristina

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Objectives: To investigate the remaining life expectancy with and without polypharmacy for Swedish women and men aged 65 years and older. Design: Age-specific prevalence of polypharmacy from the nationwide Swedish Prescribed Drug Register (SPDR) combined with life tables from Statistics Sweden was used to calculate the survival function and remaining life expectancy with and without polypharmacy according to the Sullivan method. Setting: Nationwide register-based study. Participants: A total of 1,347,564 individuals aged 65 years and older who had been prescribed and dispensed a drug from July 1 to September 30, 2008. Measurements: Polypharmacy was defined as the concurrent use of 5 or more drugs. Results: At age 65 years, approximately 8 years of the 20 remaining years of life (41%) can be expected to be lived with polypharmacy. More than half of the remaining life expectancy will be spent with polypharmacy after the age of 75 years. Women had a longer life expectancy, but also lived more years with polypharmacy than men. Discussion: Older women and men spend a considerable proportion of their lives with polypharmacy. Conclusion: Given the negative health outcomes associated with polypharmacy, efforts should be made to reduce the number of years older adults spend with polypharmacy to minimize the risk of unwanted consequences.

AB - Objectives: To investigate the remaining life expectancy with and without polypharmacy for Swedish women and men aged 65 years and older. Design: Age-specific prevalence of polypharmacy from the nationwide Swedish Prescribed Drug Register (SPDR) combined with life tables from Statistics Sweden was used to calculate the survival function and remaining life expectancy with and without polypharmacy according to the Sullivan method. Setting: Nationwide register-based study. Participants: A total of 1,347,564 individuals aged 65 years and older who had been prescribed and dispensed a drug from July 1 to September 30, 2008. Measurements: Polypharmacy was defined as the concurrent use of 5 or more drugs. Results: At age 65 years, approximately 8 years of the 20 remaining years of life (41%) can be expected to be lived with polypharmacy. More than half of the remaining life expectancy will be spent with polypharmacy after the age of 75 years. Women had a longer life expectancy, but also lived more years with polypharmacy than men. Discussion: Older women and men spend a considerable proportion of their lives with polypharmacy. Conclusion: Given the negative health outcomes associated with polypharmacy, efforts should be made to reduce the number of years older adults spend with polypharmacy to minimize the risk of unwanted consequences.

KW - Aged

KW - Drug use

KW - Life expectancy

KW - Polypharmacy

KW - Sex difference

UR - http://www.scopus.com/inward/record.url?scp=84955183659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955183659&partnerID=8YFLogxK

U2 - 10.1016/j.jamda.2015.07.015

DO - 10.1016/j.jamda.2015.07.015

M3 - Article

AN - SCOPUS:84955183659

VL - 17

SP - 31

EP - 35

JO - Journal of the American Medical Directors Association

JF - Journal of the American Medical Directors Association

SN - 1525-8610

IS - 1

ER -